Table 5.
Studies performed on animals to investigate the function of miRNA-93 in non-cancerous disease
| Disease type | micRNA type | Animal model | Result | Ref |
|---|---|---|---|---|
| Parkinson’s Disease | miRNA‑93 |
A mouse model of PD induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) |
By controlling STAT3 expression in the MPTP-induced PD mouse model, miRNA-93 lessens neuronal damage and decreases inflammatory response | [25] |
| Hepatic injury | miRNA-93 | Rat I-R hepatic injury model | MiRNA-93 inhibits STAT3, to reduce hepatic damage during ischemia–reperfusion | [106] |
| Prolactinoma | miRNA-93 | Rat, Female athymic nude mice | MicroRNA-93 targets ATG7 in prolactinoma to mediate cabergoline resistance | [107] |
| Diabetic nephropathy | miRNA-93-5p | A total of 48 C57BL/6 mice (age: 6–8 weeks, weight: 20–24 g) were used | The prevention of renal interstitial fibrosis in DN was enhanced by silenced XIST causing miRNA-93-5p-dependent CDKN1A suppression, suggesting a potential future method for DN progression prevention | [108] |